Journal article
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
F Santoro, OA Botrugno, R Dal Zuffo, I Pallavicini, GM Matthews, L Cluse, I Barozzi, S Senese, L Fornasari, S Moretti, L Altucci, PG Pelicci, S Chiocca, RW Johnstone, S Minucci
Blood | AMER SOC HEMATOLOGY | Published : 2013
Abstract
Aberrant recruitment of histone deacetylases (HDACs) by the oncogenic fusion protein PML-RAR is involved in the pathogenesis of acute promyelocytic leukemia (APL). PML-RAR, however, is not sufficient to induce disease in mice but requires additional oncogenic lesions during the preleukemic phase. Here, we show that knock-down of Hdac1 and Hdac2 dramatically accelerates leukemogenesis in transgenic preleukemic mice. These events are not restricted to APL because lymphomagenesis driven by deletion of p53 or, to a lesser extent, by c-myc overexpression, was also accelerated by Hdac1 knock-down. In the preleukemic phase of APL, Hdac1 counteracts the activity of PML-RAR in (1) blocking differenti..
View full abstractGrants
Awarded by Fondazione Italiana per la Ricerca sul Cancro
Funding Acknowledgements
Work in S.M.'s laboratory is supported by AIRC (Italian Association for Cancer Research), FIRC (Italian Foundation for Cancer Research), CNR (National Research Council), Flagship Project Epigen, MIUR and MIS (Ministry of Health and Research), and European Community (FP7 Blueprint and 4D Projects).R.W.J. is a Principal Research Fellow of the National Health and Medical Research Council of Australia (NHMRC) and is supported by NHMRC program and project grants, Cancer Council Victoria, The Leukemia Foundation of Australia, Victorian Breast Cancer Research Consortium, and the Victorian Cancer Agency.